475 0 Kommentare Response Biomedical Corp. Completes Going-Private Transaction

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 29, 2016) - Response Biomedical Corp. ("Response" or the "Company") (TSX:RBM)(OTC:RPBIF) is pleased to announce that the previously announced acquisition of all the issued and outstanding common shares of Response ("Response Shares") by 1077801 B.C. Ltd., a company beneficially owned by OrbiMed Asia Partners, L.P., OrbiMed Private Investments III, LP, OrbiMed Associates III, LP, OrbiMed Advisors LLC, OrbiMed Advisors Limited, Samuel D. Isaly, and Shanghai Runda Medical Technology Co., Ltd. by way of a plan of arrangement (the "Arrangement") has been completed.

Pursuant to the Arrangement, Response shareholders will receive, subject to the terms and conditions of the Arrangement, $1.12 per Response Share (except in the case of certain shareholders who have agreed to roll over their Response Shares and will instead receive shares of 1077801 B.C. Ltd.) and Response will become a wholly-owned subsidiary of 1077801 B.C. Ltd.

The Arrangement was approved by the Supreme Court of British Columbia in its final order dated September 19, 2016. The Arrangement remains subject to final approval by the Toronto Stock Exchange (the "TSX").

The delisting of the Response Shares from the TSX is expected to occur at the close of business on or about December 2, 2016.

Additional information regarding the terms of the Arrangement is set out in Response's management information circular dated August 11, 2016, which is available under Response's profile at www.sedar.com.

About Response Biomedical Corp.

Response develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP^® platform for clinical, biodefense and environmental applications. RAMP^® represents a unique paradigm in diagnostics that provides reliable, quality results in minutes. The RAMP^® platform consists of a reader and single-use disposable test cartridges and has the potential to be adapted to any other medical and non-medical immunoassay based test currently performed in laboratories. Response clinical tests are commercially available for the aid in early detection of heart attack, congestive heart failure, thromboembolism, sepsis, influenza A and B and RSV. In the non-clinical market, RAMP^® tests are currently available for the environmental detection of West Nile Virus and Dengue Fever antigen and for Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Response is a publicly traded company listed on the TSX under the trading symbol "RBM" and quoted on the OTC under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.